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PURPOSE:
The purpose of this learning activity is to provide information about the etiology and treatment of atrophie blanche.
TARGET AUDIENCE:
This continuing education activity is intended for physicians and nurses with an interest in skin and wound care.
OBJECTIVES:
After participating in this educational activity, the participant should be better able to:
1. Discuss the pathophysiology of atrophie blanche.
2. Explore treatment options for livedoid vasculopathy.
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ABSTRACT
Atrophie blanche (AB) is a porcelain-white scar that may be seen
at the base of a healed ulcer or in association with livedoid
vasculopathy (LV). The term AB originally had been used
synonymously with LV, whereas LV is a noninflammatory
thrombotic condition presenting as either a primary or secondary
event (often associated with coagulation).
KEYWORDS: atrophie blanche, venous disease, livedoid
vasculopathy
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INTRODUCTION
Atrophie blanche (AB) is a common clinical sign in patients with
leg ulcers, which may be a consequence of venous hypertension
with local involvement or part of a livedoid vasculopathy (LV).
It presents as atrophic porcelain satellite scars with peripheral
telangiectasia and hyperpigmentation. Atrophie blanche is a
morphological feature that is commonly seen following a healed
ulcer with venous stasis and other etiologies. In cases of AB as-
sociated with LV, the morphologic feature of AB presents as a
primary lesion and in locations such as the dorsum of the foot and
may precede ulceration. The terms hyalinizing vasculitis, AB, and
LV have been used synonymously in the literature, whereas LV
is a disease process with characteristic histology, and AB repre-
sents a morphological healing pattern that is the result of several
different pathological processes including venous leg ulcers.1
Thus, the 2 forms of AB: (1) the AB-LV complex and (2) AB in the
context of chronic venous insufficiency, are unrelated and require
separate diagnostic and therapeutic approaches.1,2 This continuing
education article focuses on the literature to clarify the misnomer
of AB as a disease and review LV as a thrombo-occlusive disorder.
CASE 1
A 60-year-old female retired teacher presented with a long
history of varicose veins, vein stripping, and recurrent leg ulcers. On
physical examination, she had a painful area of scarring on the
medial ankle surrounded by white atrophic patches of AB (Figure 1).
History of Atrophie Blanche
Atrophie blanche was originally described in 1929 by Milian3
as a particular form of cutaneous atrophy called ‘‘AB en plaque’’
presenting as a smooth, ivory-white, plaque-like area on lower
extremities surrounded by a hyperpigmented border and telangi-
ectatic blood vessels.3,4 He associated the lesions with syphilis and
tuberculosis, but Gonin5 linked 70% of cases to vascular disorders.
Gougerot and Hamburger6 postulated the lesions are a result of
capillaritis and concluded that AB is a variant of stasis dermatitis.
In 1950, Nelson described AB with fibrinous histological occlusion
of blood vessels.7
Pathogenesis
The pathogenesis of AB involves small-vessel thrombosis of
the subpapillary vascular plexus.8 Following the thrombosis,
megacapillaries (red dots) may arise within a white area of AB as
a repair mechanism. This is seen as a common finding in not only
a subset of patients with chronic venous insufficiency, but also in
those with other entities.
CASE 2
A 56-year-old woman presented to the clinic with a leg ulcer on
the lateral ankle extending to the dorsum of the feet. Her history
is significant for 2 episodes of deep vein thrombosis and recur-
rent leg ulcers. On physical examination, the patient had small
pinpoint ulcers and areas of white atrophic patches in the peri-
wound areas with associated telangiectasia (Figure 2).
History of Livedoid Vasculopathy
Livedoid vasculopathy has been given multiple names in the
literature including livedo vasculitis, segmental hyalinizing
vasculitis, livedo reticularis with summer ulceration, Milian white
atrophy, AB en plaque, and PURPLE (painful Purpuric Ulcers with
Reticular Pattern of Lower Extremities), among others.9 Early
descriptions of LV with the designation of livedoid vasculitis and
Figure 1.
CHRONIC VENOUS INSUFFICIENCY
Painful areas of scarring on the medial ankle surrounded by white atrophic patches of AB.
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segmental hyalinizing vasculitis originated from Mayo Clinic.10,11
The clinical appearance of livedo reticularis may relate to dilated
or contracted blood vessels in addition to hyalinizing disorders.
Pathogenesis of Livedoid Vasculopathy
Livedoid vasculopathy is a thrombo-occlusive disorder asso-
ciated with several biochemical defects that may resolve with
ivory white scars or AB. The occlusion of blood vessels by fibrin
thrombi is a primary event in this context.12 Several cases have
been reported in association with other conditions, such as with
the lupus-type anticoagulant, hyperhomocysteinemia,13 increased
levels of anticardiolipin, protein C deficiency,14 cryoglobulinemia,
factor V Leiden mutation,15 plasminogen activator inhibitor 1
promoter mutation,15 and antithrombin III deficiency.12,16 There
is evidence for a decrease in fibrinolytic activity and an increase in
thrombogenic activity in patients with LV. Increased platelet ex-
pression of P selectin is linked to abnormal platelet function in
patients with LV.17 Hyperhomocysteinemia is considered to be a
thrombophilic condition that has been seen in association with
LV.18–20 Overall, LV is mainly a thrombo-occlusive vasculopathy,
and the thrombotic event may be due to multiple mechanisms.
CLINICAL PRESENTATION: ATROPHIE
BLANCHE VS LIVEDOID VASCULOPATHY
An association of AB with venous insufficiency is the most
common association because of the high prevalence of venous
disease.21,22 Patients with chronic deep venous insufficiency of
the short saphenous vein can develop AB on the dorsal foot,
often at the base of the second to fourth toe. However, the in-
volvement beyond bilateral malleoli, extending to the dorsal aspect
of the feet and toes, is consistent with the secondary form of LV.20
The estimated incidence of LV has been reported as 1:100 000
with female predominance.9,12 The initial appearance of
telangiectatic purpuric papules and plaques (Figure 2) is followed
by the formation of crusted ulcers and subsequently residual
white atrophic stellate scars (Figure 3). The ulcers are painful, often
bilateral, may be slow to heal, and often recur. The common loca-
tions for these ulcers are primarily in the medial ankle region and
less commonly on the dorsum of the feet19 (Figure 3).
Hairston et al20 documented the lower extremity was involved
in all patients, with lesions on the following locations: lower
leg 80%, ankle 66.7%, and foot 62.2%. The white ivory scars or
AB was seen in 71% of LV patients, and this clinical pattern has
been reported either without previous ulceration, or following a
painful ulcerative stage.20 Of the 45 patients, 19 showed associated
comorbid conditions, including collagen vascular disease (6) and
malignancies (5).20
In patients with LV, the association with numerous hetero-
geneous coagulation abnormalities has been reported in more
than 50% of cases. These abnormalities include factor V Leiden
mutation (heterozygous), decreased activity for protein C or pro-
tein S, prothrombin G20210A gene mutation, anticardiolipin anti-
bodies, elevated homocysteine level, and lupus anticoagulant.
Figure 2.
LIVEDOID VASCULOPATHY
Painful areas of scarring on lateral ankle extending to dorsum of foot surrounded by white
atrophic patches of AB.
Figure 3.
THE COMMON LOCATION FOR LV IS ANKLE REGION AND
LESS COMMONLY ON THE DORSUM OF THE FEET
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Fifty percent of patients had no identifiable association with a
coagulation disorder, a coagulopathy, or a vasculitis.20
Di Giacomo et al16 demonstrated pro-coagulable laboratory
abnormalities in 52% (18 of 34). Among the laboratory abnor-
malities, a mutation in factor V Leiden was detected also in
17.64%, antiphospholipid antibody in 17.64%, protein C deficiency
in 8.82%, and hyperhomocysteinemia in 5.88%. These findings
emphasize the need for thrombophilic factor investigations in all
patients with clinical and pathological features of LV. In a ret-
rospective study of 70 Asian patients with LV, the association with
collagen vascular disease (3%) and venous insufficiency (6%) was
lower than Western studies.21
HISTOPATHOLOGY OF LIVEDOID
VASCULOPATHY
Histopathologic changes of LV are segmental and vary with the
age of the lesion. The biopsy of an uninvolved segment may not
demonstrate the histological features. The 3 typical LV blood
vessel histological features include intraluminal thrombosis, en-
dothelial proliferation, and subintimal hyaline degeneration. In
the histopathology of these patients, nearly all (97.8%) demon-
strated dermal blood vessel thrombosis. Direct immunofluores-
cence was positive for fibrin > C3 > immunoglobulin M (IgM) in
86.1% of samples.12,20
In the early stage, the lumen of small blood vessels in the upper
and mid dermis demonstrate hyaline thrombi with the vessel
walls containing fibrinous material. In the presence of ulceration,
infarction of the superficial dermis is seen.18 Extravasated red
blood cells may present in the upper dermis.9,18,22 A nonspecific
papillary dermis increase in small blood vessels is a common
biopsy finding. Biopsies from partially developed lesions dem-
onstrate a thickening and hyalinization of vessel walls in the
superficial dermis with some endothelial edema and proliferation.
This is similar to the nonspecific change at the base of leg ulcers.
In older lesions, dermal sclerosis and scarring with some dilated
lymphatic vessels are often associated with epidermal atrophy.
Immunofluroscent stained skin biopsies may demonstrate fibrin
in vessel walls in early lesions and immunoglobulins (IgG and
IgM) and complement (C3) in the later lesions.23 The immuno-
logic reaction is most likely a secondary rather than a primary
event related to the pathogenesis of this vasculopathy.22,24,25
EVALUATION OF ATROPHIE BLANCHE VS.
LIVEDOID VASCULOPATHY
In the presence of venous hypertension and distribution of
lesions around the corresponding malleolus, no primary workup
for coagulation disorders and inflammatory disorders is required
(Table 1). The finding of white satellite scars on the lower legs
with or without ulceration is sufficient to prompt a workup to
assess the inflammatory and noninflammatory differential diag-
noses (Figure 2). A thorough evaluation with a focus on personal
or family history of hypercoagulable disorders, fibrinolytic
Table 1.
COMPARISON OF ATROPHIE BLANCHE ASSOCIATED WITH HEALED VENOUS ULCER WITH ATROPHIE BLANCHE
ASSOCIATED WITH LIVEDOID VASCULOPATHY
Characteristics AB Associated with Healed Venous Ulcer AB Associated with Livedoid Vasculopathy
Location Most commonly on medial ankle Medial and lateral ankle
Extending to dorsum of foot
History Usually follows an ulcer May precede, occur at the same time, or follow an ulcer
Morphology White atrophic scar with areas of megacapillaries White atrophic scar with areas of megacapillaries plus
livedo reticularis
Coagulopathy Occasional More common (up to 50%)
Associations Varicose veins Has 2 forms of primary and secondary (the secondary
form is associated with connective tissue disease,
hematologic disorders, and paraproteinemia)
Lipodermatosclerosis
Management Compression therapy Anticoagulants
Medical intervention including pentoxifylline Antifibrinolytics
Surgical intervention Immunosuppressant
Immunomodulators
Vasodilators
Compression therapy
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disorders, and inflammatory disease is also required. A skin biopsy
for regular histology and immunofluorescence may be useful in
determining the diagnosis of LV. A sufficient skin biopsy should
include the ulcer marginal epithelium to avoid a nonspecific his-
tology with granulation tissue or inflammatory cells. Ideally, it should
be a deep punch or excisional biopsy. Further laboratory investi-
gation depends on the presence of any associated clinical features.
Extensive coagulation screening can exclude potential prothrombotic
conditions.26 Laboratory investigations are focused on the exclu-
sion of the 5 primary types of underlying diseases (remember with
the mnemonic Fibrin CHIP):
Fibrinolytic disorders
Collagen vascular disease
Hypercoagulable states
Infectious associations
Paraproteinemia.
Based on the authors’ experience, LV must be distinguished
from other conditions that produce similar cutaneous lesions on
the legs, including cutaneous polyarteritis nodosa, true small and
medium vessel cutaneous vasculitis (connective tissue diseases
and antineutrophil cytoplasmic antibody–related vasculitis),
pyoderma gangrenosum, cryoglobulinemic vasculitis, warfarin-
induced cutaneous necrosis, and cutaneous ulcers due to primary
antiphospholipid syndrome. One of the main differential diag-
noses for the reticulate ulcerative stage is polyarteritis nodosa,
which may present with purple lesions, livedo racemosa (irreg-
ular broken circles), reticulate (net-like) ulcers, subcutaneous
nodules, and scars similar to AB.
To confirm a diagnosis of cutaneous polyarteritis nodosa, a
deep wedge skin biopsy of a nodule including dermis and
subcutaneous fat is required. The main pathology is located at
the dermal subcutaneous junction with the arterioles demon-
strating transmural neutrophils acutely or mononuclear peri-
vascular infiltrates in the chronic stages.
TREATMENT OF ATROPHIE BLANCHE
The association of varicose veins in 20% to 75% of patients
with AB highlights the need for compression therapy in the
management of these patients.12,18,19,27 Treatment of associ-
ated edema is important. Multiple studies demonstrated the
role of compression therapy in fibrinolysis.28 Allenby et al29 dem-
onstrated that the antithrombotic properties of the intermittent
compression were due to fibrinolytic enhancement caused by the
intermittent venous compression. Pain control is another essen-
tial part of the management. The pain is due to multiple factors
including local ulcer formation, vascular occlusion, and coexist-
ing venous disease.
Ulcer-related pain is often localized in the wound margin and
may be maximal at the 3 stages of dressing change (dressing re-
moval, with cleansing or debridement). Using silicone adhesives
instead of acrylates will help with pain and trauma on dressing
removal. Surgical debridement is more painful than autolytic
methods with calcium alginate hydrogels or hydrocolloids. Me-
chanical irrigation should be replaced with compresses. A com-
press consists of dipping a gauze in saline and ringing out the
gauze prior to application to the wound surface. This process re-
sults in an astringent action (coagulates protein) with a net move-
ment of fluid or exudate from the wound surface to the gauze.
A soak can move fluid from a saline soaked gauze that is not
squeezed to remove the excess fluid but applied dripping wet. The
net movement is from the gauze to the wound surface and results
in the hydration of a dry wound surface. The AB associated pain
is usually due to vascular occlusion and represents a combina-
tion of nociceptive (stimulus dependent: gnawing, aching, tender,
throbbing) and neuropathic components (spontaneous: burning,
stinging, shooting, stabbing). This pain is best managed using the
World Health Organization ladder for nociceptive pain30: acetyl-
salicylic acid, nonsteroidal anti-inflammatory drugs, short- and
long-acting narcotics). Treatment of the neuropathic component
starts with tricyclics (amitriptyline or anti-noradrenaline–specific
agentsVnortriptylene or desipramine with less drowsiness) given
as a single dose at night starting with 10 to 30 mg. If these are
unsuccessful or not tolerated, gabapentin, pregabalin, or carba-
mazepine can be added in increasing but divided daily doses.31,32
Coexisting venous disease requires compression. In the absence
of arterial disease, high compression can be used (palpable pulse
and ankle brachial pressure index >0.8); however, compression
should be modified for values between 0.6 and 0.8.33 In general, if
pain is an issue from venous edema, utilizing nonelastic systems
will have less pressure at rest and lower level of associated pain.
As edema and pain control is achieved, elastic systems can be
gradually introduced.
TREATMENT OF LIVEDOID VASCULOPATHY
Management of LV remains controversial. The evidence for
the efficacy of the commonly used therapeutic modalities is
limited. Antiplatelet drugs22,34,35 and antithrombotic agents
(fibrinolytic and anticoagulant medications)24,36,37 have been
used with some success. There is no consensus on the dose of
anticoagulants in LV, but most studies administered the dose
for prevention of deep vein thrombosis.16
Other treatments include stanozolol,38 danazol,38–40 sulfasala-
zine,41,42 nicotinic acid,22,43 intravenous immunoglobulin (IVIG),44
psoralen and UV light therapy (PUVA),40,45,46 hyperbaric oxygen,47,48
doxycycline,49 and cyclosporine. Callen27 suggested cessation of
smoking, low-doseaspirin, oral pentoxyfylline,andoral dypiridamole.
Recent studies have demonstrated that anticoagulants are a well-
tolerated, effective therapeutic option for patients with LV.16,50
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The role of pentoxyfylline in the treatment of venous and arte-
rial leg ulcers has been supported by several studies.51 The he-
morheological effects of pentoxyfylline include the improvement
of local hyperviscosity and hyperaggregability of erythrocytes
or platelets, erythrocyte fluidity, and hypercoagulability, all of
which may result in improved skin oxygenation.51,52 Pentoxyfylline
has also been ordered for the treatment of LV with success, prob-
ably due to different mechanisms including a reduction of blood
viscosity, increase in the flexibility of blood cells, and increase in
inflow perfusion.37,53,54 Although the mode of action of IVIG is
not completely understood, it induces modulation of cytokine pro-
duction, neutralization of pathogens, and inhibition of complement-
mediated damage and blockage of Fas receptors.55 The role of
IVIG in vasculitis includes neutralizing circulating antibodies and
tissue deposited immune complexes.44,56 Multiple case studies have
demonstrated the response of patients with LV to IVIG with min-
imal complications.57 Cessation of smoking may also be beneficial.
CONCLUSIONS
Patients with AB commonly present in wound care clinics either
following a healed ulcer or without preceding ulceration. Atrophie
blanche is a morphologic pattern of tissue damage with scarring,
and LV is thought to be a clinicopathologic entity caused by a
variety of underlying conditions, not all of which have been
identified. Clinicians must be alert to possible systemic associa-
tions. A multiprofessional approach for the management of these
patients including pain control is optimal.
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& AB or white atrophic scars are associated with both venous
disease and LV.
& AB associated with venous disease is often localized above
the medial malleoli.
& AB associated with LV is more extensive with lesions extending
over the malleoli bilaterally and radiating to the dorsum of the
feet.
& LV is a thrombo-occlusive condition often associated with
abnormalities in fibrinolysis or CHIP disorders (collagen
vascular disease, hypercoagulable states, infections, paraproteins).
& Thrombophilia screening may have limited direct thera-
peutic impact but may be useful for genetic counseling.
& Antiplatelet, antithrombotic, fibrinolytic, and anticoagulant
medications have been used with success in the manage-
ment of AB and LV.
& A multiprofessional approach to the management of
patients with livedoid vasculopathy is required.
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